|
|
|
New ECNP logo!
“We were looking for something that better captured the boldness of the College and its aspirations.”
With these words of ECNP President Gitte Moos Knudsen, we proudly present the brand new ECNP logo!
|
|
|
|
35th ECNP Congress: invitation to industry
The bridge between basic science and real-world treatment is fundamental and the central organising principle of the ECNP Congress. Providing our participants with access, therefore, to the latest high-quality research, information, services, and solutions from the industrial sector is critical to the congress’s mission.
ECNP invites companies and organisations involved in clinical and pre-clinical research, diagnosis and treatment of disorders of the brain to contribute to the congress’s educational function.
We welcome participation in a variety of ways. We have several opportunities for companies at different price levels:
- Industry Sessions
- Exhibition
- Unrestricted educational grants
- Group registration
- Group hotel reservation
Visit the industry section on the congress website for more information and deadlines.
|
|
|
|
New Frontiers Meeting: apply by 18 January
The deadline for application to the ECNP New Frontiers in Digital Health Meeting has been extended until 18 January 2022.
This face-to-face meeting takes place in Nice, France on 20-21 March 2022.
Topics:
• Decentralised trials in CNS
• Digital (mobile) endpoints
• Digital therapeutics
The New Frontiers in Digital Health Meeting is designed for stakeholders from IT, pharma and medical devices industry, regulators, and patient and family associations who are interested in discussing how digital health is going to change the way clinical trials are run and the use of digital therapeutics for brain disorders.
|
|
|
|
On-demand access until 13 January 2022
Did you know registered participants can still view the sessions of the 34th ECNP Congress Hybrid on-demand via the online congress platform?
This is still possible until 13 January 2022, so if you missed any sessions, be quick to watch them!
|
|
|
|
Call for session proposals
ECNP is beginning to put together our exciting scientific programme for the 36th ECNP Congress, 7-10 October 2023, Barcelona, Spain, with a broad range of topics.
The Scientific Programme Committee (SPC) invites you to contribute by submitting a proposal for a full session in applied and translational neuroscience. The SPC welcomes session proposals from various disciplines, including basic brain science, applied neuroscience, psychiatry, neurology and psychology.
Submission deadline: 2 March 2022 (23.59 CET).
|
|
|
|
2022 ECNP Child and Adolescent School
The programme of the ECNP School of Child and Adolescent Neuropsychopharmacology 2022 is now online!
This School has been established to encourage and spread excellence in clinical neuropsychopharmacology among early career child and adolescent psychiatrists.
It is an interactive meeting with an international faculty of experts in basic and clinical paediatric neuropsychopharmacology. The School will be held in Venice, Italy, from 27 March-1 April 2022.
Browse the programme here:
Application is open until 13 January 2022.
|
|
|
|
Workshop on Clinical Research Methods
Last month, the ECNP Workshop on Clinical Research Methods took place in Barcelona, Spain.
Thirty-eight Early Career Scientists from 22 countries and 10 faculty from three different countries came together to hear the latest in critical approaches to clinical research from European scientific leaders.
The next ECNP Workshop will take place in November 2022. Application opens on 28 February 2022.
Tuition, accommodation and catering costs are covered by ECNP.
|
|
|
|
Interview with Martien Kas
Martien Kas is interviewed by Tom Parkhill (ECNP). Professor Kas is the PRISM2 academic project co-ordinator and professor of Behavioural Neuroscience at the University of Groningen, The Netherlands.
The interview explains how this path-breaking European project is using quantitative neurobiological parameters to better understand the processes underlying brain disorders and to improve the diagnosis and treatment of neuropsychiatric diseases.
Read the interview.
|
|
|
|
|
|